Mark Fendrick, MD, and Nicholas Bagley, JD, discuss how the ruling in Braidwood v Becerra could affect availability of preventive care.
A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design at the University of Michigan and the co–editor in chief of The American Journal of Managed Care®, and Nicholas Bagley, JD, professor at Michigan Law at the University of Michigan, spoke about how the Braidwood v Becerra ruling could affect cancer screening and other similar preventive care treatments.
Transcript
How will this ruling affect preventive services in cancer screening?
Fendrick: Yeah, currently, there are 4 cancers that either have an A or B rating from the US Preventive Services Task Force [USPSTF] or a recommendation from HRSA (Health Resources and Service Administration] regarding screening. These include breast cancer screening, colorectal cancer screening, cervical cancer screening, and lung cancer screening. The good news is currently there is some overlap in breast cancer screening and cervical cancer screening with HRSA so that if the task force ruling is upheld, there will be some cancer screenings maintained. I have been told by legal scholars such as Professor Bagley, which I'd like him to comment on, that even though we are still reeling from the fact that this initial ruling pertains only to the task force recommendations prior to 2010, I have heard some rumblings about actually having some of these other preventive services that are currently "spared" by Judge [Reed] O'Connor's ruling that may come back into place. So I worry about the 46 and have been focusing on those A- and B-rated services. But would love to hear your thoughts about potentially what might happen going down the road or prognosticating about those services defined by the CDC or HRSA that currently are spared, but are they going to come back into play?
Bagley: Yeah, I think they very well could. So the Affordable Care Act delegates to 3 different bodies the authority to designate certain services and the [USPSTF] is 1 of those. Judge O'Connor turned back challenges to the decisions made by the other 2. One of those is the Advisory Committee on Immunization Practices [ACIP], and the other is HRSA. These 2 bodies are are slightly different than USPSTF in how they're staffed and who's on them and how they make decisions. But they are the entities that say that immunizations are actually covered with zero cost sharing, and they're the ones who also protect women's preventive services. So not only cervical cancer screening and breast cancer screening, but also, and somewhat more controversially, contraception coverage. So the plaintiffs challenged all of them and lost with respect to the recommendations from ACIP and HRSA.
When the government appeals, the plaintiffs will cross-appeal and will raise their challenges about the contraception mandate and about immunization coverage. And, you know, it's quite possible that they'll win even bigger at the Court of Appeals than they wanted. That has me worried. I think the preventive services in general, losing them would be a very big deal, and losing $0 coverage of contraception would be a very big deal for similar reasons, especially because many forms of the most effective kinds of contraception, the long-acting contraception, are quite expensive. And for women who are looking to get an [intrauterine device] or other contraceptive, it's going to be tempting for employers and insurers to start asking them to pony up some cash in order to get that. And we're gonna get fewer and less contraception coverage, especially among young, price-sensitive women who are exactly the people you would like to be going after that kind of care.
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More